Wednesday, July 8, 2026

biotech · Colorectal Cancer · Psoriatic Arthritis, Rheumatoid Arthritis · CRDF

Cardiff Oncology

Cardiff Oncology clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

11055 Flintkote Avenue, San Diego, California 92121, US HQ
1999 Founded
51 Employees
Public company Type
CRDF · NYSE Ticker
Company details
Status
Public
HQ
11055 Flintkote Avenue, San Diego, California 92121, US
Founded
1999
Employees
51
Programs
58
Drugs
62
Patents
69
Intelligence · Clinical Programs

Cardiff Oncology projects

8 ClinicalTrials.gov programs sponsored by Cardiff Oncology.

Cardiff Oncology has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Atenolol

    Cardiff Oncology

    Marfan Syndrome

    approved small molecule completed

    1 trial
  2. Bimatoprost

    Cardiff Oncology

    Graves' Ophthalmopathy

    approved small molecule completed

    1 trial
  3. Carvedilol

    Cardiff Oncology

    Cirrhoses, Liver

    approved small molecule active

    1 trial
  4. Carvedilol

    Cardiff Oncology

    Cirrhosis, Liver

    approved small molecule active

    1 trial
  5. Folic Acid

    Cardiff Oncology

    Depression

    approved small molecule completed

    1 trial
  6. Pharmacokinetic based dosage change

    Cardiff Oncology

    Severe Haemophilia A

    approved small molecule completed

    1 trial
  7. Synacthen (Tetracosactrin)

    Cardiff Oncology

    Healthy

    approved small molecule completed

    1 trial
  8. ketamine

    Cardiff Oncology

    Healthy Volunteers

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Cardiff Oncology have?

8 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.